Suzhou Zelgen Biopharmaceuticals Co., Ltd.
SSE:688266.SS
114.92 (CNY) • At close June 6, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) CNY.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 532.954 | 386.439 | 302.305 | 190.361 | 27.661 | 0 | 1.311 | 0 | 0.2 |
| Cost of Revenue
| 36.991 | 31.423 | 26.161 | 6.269 | 0.027 | 33.268 | 0.894 | 5.087 | 0.16 |
| Gross Profit
| 495.963 | 355.016 | 276.144 | 184.092 | 27.633 | -33.268 | 0.417 | -5.087 | 0.041 |
| Gross Profit Ratio
| 0.931 | 0.919 | 0.913 | 0.967 | 0.999 | 0 | 0.318 | 0 | 0.202 |
| Reseach & Development Expenses
| 387.999 | 496.33 | 497.726 | 509.394 | 314.198 | 183.842 | 142.805 | 158.823 | 61.077 |
| General & Administrative Expenses
| 22.642 | -18.1 | 53.889 | 51.606 | 43.227 | 246.941 | 312.602 | 7.576 | 73.626 |
| Selling & Marketing Expenses
| 133.826 | 119.405 | 227.685 | 139.742 | 35.07 | 7.83 | 0 | 0 | 0 |
| SG&A
| 156.467 | 100.41 | 281.575 | 191.348 | 78.297 | 254.771 | 312.602 | 7.576 | 73.626 |
| Other Expenses
| 106.54 | 0 | 0.667 | -14.019 | -6.826 | 1.656 | -0.01 | -0.001 | 5.365 |
| Operating Expenses
| 651.006 | 652.798 | 779.967 | 686.723 | 385.669 | 440.268 | 446.101 | 148.326 | 134.966 |
| Operating Income
| -155.043 | -408.795 | -503.823 | -502.631 | -358.036 | -439.789 | -442.648 | -146.467 | -133.633 |
| Operating Income Ratio
| -0.291 | -1.058 | -1.667 | -2.64 | -12.944 | 0 | -337.601 | 0 | -667.051 |
| Total Other Income Expenses Net
| -0.005 | 109.71 | -2.397 | -6.103 | -0.005 | 0.001 | -0.01 | -0.001 | 5.365 |
| Income Before Tax
| -155.048 | -299.085 | -487.955 | -465.147 | -304.833 | -439.788 | -442.658 | -146.468 | -128.268 |
| Income Before Tax Ratio
| -0.291 | -0.774 | -1.614 | -2.444 | -11.02 | 0 | -337.608 | 0 | -640.27 |
| Income Tax Expense
| -4.749 | -3.95 | -2.005 | -3.156 | 5.843 | 8.196 | -0.78 | -0.057 | 0.044 |
| Net Income
| -137.831 | -278.583 | -485.949 | -461.991 | -310.675 | -447.984 | -440.089 | -146.468 | -128.268 |
| Net Income Ratio
| -0.259 | -0.721 | -1.607 | -2.427 | -11.232 | 0 | -335.649 | 0 | -640.27 |
| EPS
| -0.52 | -1.09 | -2.02 | -1.92 | -1.29 | -1.87 | -2.45 | -0.81 | -0.71 |
| EPS Diluted
| -0.52 | -1.09 | -2.02 | -1.92 | -1.29 | -1.87 | -2.45 | -0.81 | -0.71 |
| EBITDA
| -70.555 | -214.226 | -402.207 | -405.554 | -256.63 | -405.002 | -437.351 | -141.381 | -129.193 |
| EBITDA Ratio
| -0.132 | -0.554 | -1.33 | -2.13 | -9.278 | 0 | -333.561 | 0 | -644.886 |